...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Cost-effectiveness analysis of the 10-and 13-valent pneumococcal conjugate vaccines in Argentina
【24h】

Cost-effectiveness analysis of the 10-and 13-valent pneumococcal conjugate vaccines in Argentina

机译：阿根廷10价和13价肺炎球菌结合疫苗的成本效益分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Since the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) were recently licensed for use in Argentina, both vaccines were evaluated to estimate the costs, health benefits and cost-effectiveness of adding a PCV to the routine child immunization schedule.Methodology: The integrated TRIVAC vaccine cost-effectiveness model from Pan American Health Organization's ProVac Initiative (Version 1.0.65) was used to assess the health outcomes of 20 successive cohorts from birth to 5 years of age. PCV-10 and PCV-13 were each compared to a scenario assuming no PCV vaccination. A 3 + 1 (three doses + booster) schedule and a vaccination price of US$ 20.75 per dose was assumed in the base case for both vaccines.Results: Introduction of PCV-13 rather than PCV-10 would increase the number of life years gained (LYG) by at least 10%. The number of LYG (and LYG after adjustment for DALY morbidity weights) was 56,882 (64,252) for PCV-10 compared to 65,038 (71,628) for PCV-13. From the health system perspective, the cost per DALY averted was US$ 8973 and US$ 10,948 for PCV-10 and PCV-13 respectively, and US$ 8546 and US$ 10,510 respectively, after incorporating costs saved by households. When PCV13 was compared to PCV10 directly, the additional benefits of PCV-13 was conferred at a cost of US$ 28,147 per DALY averted. Cost-effectiveness was influenced mainly by vaccine price, serotype replacement, pneumonia mortality and discount rate.Conclusion: Routine vaccination against S. pneumoniae in Argentina would be cost-effective with either PCV-10 or PCV-13. PCV-13, with higher coverage of local serotypes, would prevent more cases of pneumonia, invasive pneumococcal disease, sequelae and deaths with a higher number of LYG and DALYs averted, but PCV-10, due its higher impact in the prevention of AOM, would save more costs to the healthcare system
机译：目的：由于10价肺炎球菌结合疫苗（PCV-10）和13价肺炎球菌结合疫苗（PCV-13）最近在阿根廷获得许可使用，因此对这两种疫苗进行了评估，以评估其成本，健康益处和成本效益。方法：采用泛美卫生组织ProVac计划（1.0.65版）的综合TRIVAC疫苗成本效益模型评估了从出生到5岁的20个连续队列的健康结果年龄。将PCV-10和PCV-13分别与假设未接种PCV疫苗的情况进行了比较。两种疫苗的基本情况均假定为3 +1（3剂+加强）方案，每剂疫苗的价格为20.75美元。结果：引入PCV-13而非PCV-10可以延长寿命年限（LYG）至少提高了10％。 PCV-10的LYG（和调整了DALY发病率权重后的LYG）数量为56,882（64,252），而PCV-13则为65,038（71,628）。从卫生系统的角度来看，在计入住户节省的费用后，PCV-10和PCV-13避免每位DALY的费用分别为8973美元和10,948美元，分别为8546美元和10,510美元。当直接将PCV13与PCV10进行比较时，PCV-13的额外收益为每避免一个DALY带来28,147美元的成本。成本效益主要受疫苗价格，血清型替代，肺炎死亡率和贴现率的影响。结论：在阿根廷，常规疫苗接种肺炎链球菌对PCV-10或PCV-13而言将具有成本效益。 PCV-13具有更高的局部血清型覆盖率，可以预防更多的肺炎，侵袭性肺炎球菌疾病，后遗症和死亡，并避免了更多的LYG和DALY，但是PCV-10由于其对预防AOM的影响更大，将为医疗系统节省更多成本

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号